U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Bristol Myers' Cobenfy, recently approved by the FDA for schizophrenia, lacks a boxed warning, positioning it as a safer ...
2seventy bio and Bristol Myers Squibb are pulling the plug on a late-stage study of their Abecma gene therapy in certain people newly diagnosed with the blood cancer multiple myeloma. 2seventy on ...
Bristol-Myers Squibb Co is facing a class-action lawsuit related to a $2 billion pension risk transfer deal made five years ...
Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
West Midlands Police, ambulance fire service staff were sent to the scene but unable to save the man A Coventry man has died after falling from the balcony of a tower block. Police were called to ...
BMO Capital analyst Evan Seigerman maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) today and set a price target of $48.00. Evan Seigerman has given his Hold rating due ...
Stocks traded mixed Friday after the Federal Reserve’s preferred inflation measure showed that consumer prices continue to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback